| 000 | 01586 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250511192123.0 | ||
| 264 | 0 | _c19920424 | |
| 008 | 199204s 0 0 eng d | ||
| 022 | _a0022-1899 | ||
| 024 | 7 |
_a10.1093/infdis/165.4.676 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBryant, R E | |
| 245 | 0 | 0 |
_aBeta-lactam enhancement of aminoglycoside activity under conditions of reduced pH and oxygen tension that may exist in infected tissues. _h[electronic resource] |
| 260 |
_bThe Journal of infectious diseases _cApr 1992 |
||
| 300 |
_a676-82 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAbscess _xdrug therapy |
| 650 | 0 | 4 | _aAerobiosis |
| 650 | 0 | 4 |
_aAmikacin _xpharmacology |
| 650 | 0 | 4 | _aAnaerobiosis |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xpharmacology |
| 650 | 0 | 4 |
_aBacteroides fragilis _xdrug effects |
| 650 | 0 | 4 |
_aCefotaxime _xpharmacology |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 |
_aEnterobacteriaceae _xdrug effects |
| 650 | 0 | 4 |
_aEscherichia coli _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aHydrogen-Ion Concentration |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aOxygen _xmetabolism |
| 650 | 0 | 4 |
_aPseudomonas aeruginosa _xdrug effects |
| 650 | 0 | 4 |
_aTicarcillin _xpharmacology |
| 650 | 0 | 4 |
_aTobramycin _xpharmacology |
| 700 | 1 | _aFox, K | |
| 700 | 1 | _aOh, G | |
| 700 | 1 | _aMorthland, V H | |
| 773 | 0 |
_tThe Journal of infectious diseases _gvol. 165 _gno. 4 _gp. 676-82 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/infdis/165.4.676 _zAvailable from publisher's website |
| 999 |
_c1558679 _d1558679 |
||